GIMAP6

Across TCGA pan-cancer cohorts, GIMAP6 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of GIMAP6’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where GIMAP6 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types GIMAP6 is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

CCRCC, LSCC, and LUAD are the cancer types where GIMAP6 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GIMAP6 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	+0.960	<.001	11	view →
LSCC	Male	III,IV	−0.539	<.001	7	view →
LUAD	Female	All	−0.358	<.001	7	view →
PDAC	Female	All	+0.472	.003	4	view →
HNSC	All	II,III,IV	+0.271	.005	4	view →
OV	All	All	−3.090	.006	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

GIMAP6–CCRCC

Open the CCRCC breakdown →